Doris Benbrook to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Doris Benbrook has written about Neoplasm Recurrence, Local.
Connection Strength
0.701
-
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
Score: 0.298
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
Score: 0.125
-
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43.
Score: 0.097
-
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61.
Score: 0.077
-
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603.
Score: 0.060
-
Niclosamide causes lysosome-dependent cell death in endometrial cancer cells and tumors. Biomed Pharmacother. 2023 May; 161:114422.
Score: 0.044